Pharmacoeconomic assessment of a drug, medical device, or other healthcare product can take on many forms and occur at multiple points in the development cycle. Cost-effectiveness analysis, a major component of pharmacoeconomic assessment, has traditionally occurred in the later phases of product development—either as a piggy-back to a phase III or pivotal clinical trial, or peri-authorization.
Join Medpace experts as they explore the application of pharmacoeconomic assessment throughout all phases of clinical trials as well as in observational studies, including registries and other post-marketing data collection. Save your seat: http://bit.ly/1eucqeB
This discussion will cover topics including:
· How pharmacoeconomic assessment can be envisioned in the context of early phase product development, implemented, maintained to support product marketing, and used to inform future decision-making.
· Cost-effectiveness analysis at different phases in the product development cycle.
· Pharmacoeconomic assessment in the post-marketing context.
· Comparing and contrasting approaches for small/medium product developers relative to larger companies.
· Case studies on “real world” implementation.
Lee Walke, Vice President e-Clinical at Medpace, has nearly 25 years of progressive clinical development experience with expertise in collecting real-world outcomes and clinical data, data integration, endpoint derivation, electronic submissions, Electronic Health Records (EHR), and electronic Patient Reported Outcomes (ePRO).
Matthew J. Page, Ph.D., M.P.P., Epidemiologist at Medpace, has a diverse background in academia and research including teaching college courses in epidemiology and biostatistics and working with pharmaceutical and medical device companies to implement numerous pharmacoeconomic methodologies, including cost-effectiveness analysis and budget impact modeling.
Space is limited. Save your seat here: http://bit.ly/1eucqeB